Vitamin D3therapy in patients with asthma complicated by sinonasal disease: Secondary analysis of the Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma trial

[...]it remains unknown whether a 12-week course of treatment with vitamin D3 is sufficient to affect chronic sinonasal disease. Relative RRs between subjects assigned to receive vitamin D3 and placebo Variable No sinonasal disease, SNQ score < 1 (n = 166), no. (%) Sinonasal disease, SNQ score >= 1 (n = 242), no. (%) P value Demographics Male sex 61 (36.8) 69 (28.5) .08 Race/ethnicity   .02 Black 66 (39.8) 65 (26.9)  White 74 (44.6) 142 (58.7)  Hispanic 20 (12.1) 19 (7.9)  Other[low *] 6 (3.6) 16 (6.6)  BMI (kg/m2) 32.4 (9.8) 31.3 (8.2) .21 Age at asthma diagnosis (y) 13.7 (13.6) 15.5 (14.6) .20 Pulmonary function tests Prebronchodilator FEV1 (L) 2.6 (0.8) 2.7 (0.8) .20 Prebronchodilator FEV1 (% predicted) 78.8 (13.6) 81.9 (14.2) .03 Prebronchodilator FVC (L) 3.6 (1.0) 3.7 (1.2) .19 Prebronchodilator FEV1/FVC ratio 0.7 (0.1) 0.7 (0.1) .86 Maximum albuterol reversibility (% change [n = 406]) 16.6 (11.0) 18.2 (12.2) .19 Methacholine PC20 (n = 391) 0.6 (1.6) 0.7 (1.7) .56 Asthma characteristics ACT score 19.2 (3.2) 19.0 (3.3) .48 am symptom score (2-wk average)[dagger] 0.4 (0.3) 0.5 (0.4) .007 pm symptom score (2-wk average)[dagger] 0.4 (0.4) 0.5 (0.4) .006 am PEF (2-wk average [L/min]) 382.1 (105.2) 402.0 (104.3) .06 pm PEF (2-wk average [L/min]) 388.3 (106.8) 407.0 (105.8) .08 Sputum eosinophils (%), median (IQR [n = 338]) 0.3 (0.0-1.4) 0.4 (0.0-1.3) .33 Positive skin test results, median (IQR [n = 390]) 3 (2-5) 3 (2-6) .39 Oral steroid used during the past 12 mo 49 (29.5) 77 (31.8) .62 ICS used during the past 12 mo 69 (41.6) 108 (44.6) .54 25-Hydroxyvitamin D (ng/mL) 17.9 (6.9) 19.5 (6.6) .02 Table E1 Baseline characteristics of study subjects ACT, Asthma Control Test; BMI, body mass index, FVC, forced vital capacity; IQR, interquartile range; PEF, peak expiratory flow.